When does Pfizer report earnings and why does it matter for PFE stock?

Pfizer reports after the close on **03 Feb 2026**. The earnings release matters for PFE stock because management guidance, Paxlovid sales, and margin details can change short-term valuation and trading volume.

What valuation metrics should investors check for PFE stock?

Key metrics for PFE stock are **PE 15.37**, **EPS 1.72**, price-to-book **1.62**, and free cash flow yield near **6.90%**. These show moderate valuation and income characteristics.

What is Meyka AI's rating and price view for PFE stock?

Meyka AI rates PFE **69.95 / Grade B / HOLD**. The model baseline target is **$28.00** with forecasts of **$24.96** monthly and **$23.46** yearly. These are projections, not guarantees.

What are the main risks that could hurt PFE stock after earnings?

Main risks for PFE stock include weaker Paxlovid demand, lower vaccine revenue, margin compression, and disappointing guidance. Any surprise on capital allocation or regulatory news can amplify moves.

US Stocks

PFE Pfizer Inc. (NYSE) Market Closed 30 Jan 2026: $26.44 stock ahead of earnings

ByDanny Kontos January 31, 2026January 31, 2026

PFE stock closed at $26.44 on 30 Jan 2026 as investors brace for Pfizer Inc.’s Q4 earnings release. The company reports after the close on 03 Feb 2026, and expectations center on revenue mix, Paxlovid demand, and recent deal activity. Volume ended at 47,193,118 shares, signaling above-normal interest versus a 50-day average of 25.45. Traders will watch guidance, margin commentary, and any update on the company’s recent capital deployment for signs of an earnings-driven re-rate.